On consolidated basis
Quarter ended June 2026 compared with Quarter ended June 2025.
Net sales (including other operating income) of Natco Pharma has declined 44.68% to Rs 735.2 crore. Sales of Pharmaceutical segment has gone down 46.35% to Rs 694.40 crore (accounting for 94.45% of total sales). Sales of Agro Chemical segment has gone up 17.58% to Rs 40.80 crore (accounting for 5.55% of total sales). Profit before interest, tax and other unallocable items (PBIT) has slumped 65.47% to Rs 198.60 crore. PBIT of Pharmaceutical segment fell 64.74% to Rs 203.90 crore (accounting for 102.67% of total PBIT). PBIT of Agro Chemical segment fell 65.62% to Rs -5.30 crore (accounting for -2.67% of total PBIT). PBIT margin of Pharmaceutical segment fell from 44.68% to 29.36%. PBIT margin of Agro Chemical segment fell from negative 9.22% to negative 12.99%. Overall PBIT margin fell from 43.28% to 27.01%. Operating profit margin has declined from 42.97% to 25.37%, leading to 67.34% decline in operating profit to Rs 186.50 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 13.75% to 20.41%. Purchase of finished goods cost rose from 2.84% to 3.59%. Employee cost increased from 12.86% to 23.19%. Other expenses rose from 27.09% to 28.70%. Other income fell 4.05% to Rs 59.2 crore. PBIDT fell 61.17% to Rs 245.7 crore. Provision for interest rose 306.25% to Rs 13 crore. PBDT fell 63.03% to Rs 232.7 crore. Provision for depreciation fell 18.23% to Rs 47.1 crore. Profit before tax down 67.55% to Rs 185.60 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 63.4 crore, compared to Rs 91.6 crore. Effective tax rate was 23.49% compared to 16.02%. Minority interest was nil in both the periods. Net profit attributable to owners of the company decreased 57.04% to Rs 206.50 crore. Promoters’ stake was 49.42% as of 30 June 2026 ,compared to 49.56% as of 30 June 2025 .
Full year results analysis.
Net sales (including other operating income) of Natco Pharma has declined 7.93% to Rs 4078.3 crore. Sales of Pharmaceutical segment has gone down 9.81% to Rs 3,940.10 crore (accounting for 96.61% of total sales). Sales of Agro Chemical segment has gone up 128.05% to Rs 138.20 crore (accounting for 3.39% of total sales). Profit before interest, tax and other unallocable items (PBIT) has slumped 34.03% to Rs 1,527.50 crore. PBIT of Pharmaceutical segment fell 37.13% to Rs 1,547.30 crore (accounting for 101.30% of total PBIT). PBIT of Agro Chemical segment rose 86.42% to Rs -19.80 crore (accounting for -1.30% of total PBIT). PBIT margin of Pharmaceutical segment fell from 56.33% to 39.27%. PBIT margin of Agro Chemical segment rose from negative 240.59% to negative 14.33%. Overall PBIT margin fell from 52.27% to 37.45%. Operating profit margin has declined from 49.58% to 35.22%, leading to 34.59% decline in operating profit to Rs 1,436.50 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 12.07% to 14.18%. Purchase of finished goods cost rose from 3.74% to 4.86%. Employee cost increased from 13.38% to 16.42%. Other expenses rose from 21.37% to 30.21%. Other income fell 16.05% to Rs 297.6 crore. PBIDT fell 32.01% to Rs 1734.1 crore. Provision for interest rose 53.56% to Rs 36.7 crore. Loan funds rose to Rs 713.90 crore as of 31 March 2026 from Rs 279.40 crore as of 31 March 2025. Inventories rose to Rs 908.50 crore as of 31 March 2026 from Rs 765.80 crore as of 31 March 2025. Sundry debtors were lower at Rs 881.20 crore as of 31 March 2026 compared to Rs 1,246.60 crore as of 31 March 2025. Cash and bank balance declined from Rs 2,176.00 crore as of 31 March 2025 to Rs 1,550.90 crore as of 31 March 2026. Investments rose to Rs 3,127.10 crore as of 31 March 2026 from Rs 473.60 crore as of 31 March 2025 . PBDT fell 32.82% to Rs 1697.4 crore. Provision for depreciation fell 12.16% to Rs 206.6 crore. Fixed assets declined from Rs 2,866.00 crore as of 31 March 2025 to Rs 2,839.10 crore as of 31 March 2026. Intangible assets increased from Rs 57.40 crore to Rs 257.30 crore. Profit before tax down 34.94% to Rs 1,490.80 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 118.9 crore, compared to Rs 408 crore. Effective tax rate was 7.73% compared to 17.81%. Minority interest was nil in both the periods. Net profit attributable to owners of the company decreased 24.76% to Rs 1,418.50 crore. Equity capital stood at Rs 35.80 crore as of 31 March 2026 to Rs 35.80 crore as of 31 March 2025. Per share face Value remained same at Rs 2.00. Promoters’ stake was 49.42% as of 31 March 2026 ,compared to 49.56% as of 31 March 2025 . Cash flow from operating activities increased to Rs 1,768.30 crore for year ended March 2026 from Rs 1,696.80 crore for year ended March 2025. Cash flow used in acquiring fixed assets during the year ended March 2026 stood at Rs 391.10 crore, compared to Rs 511.60 crore during the year ended March 2025. Other Highlights
The company
declared an interim dividend of Rs 1.50
per equity share (75%) for FY27, with August 20, 2026 fixed as the record date.
In
Q1 FY27, Domestic formulations contributed 17.2% of total revenue, exports 60.1%,
Crop Health Sciences (CHS) 5.1%, API 8.4%, and others 9.2%.
The
company Received Final Approval for Eribulin Mesylate Injection
from U.S. FDA.
| Natco Pharma : Consolidated Results | | | Quarter ended | Year ended |
|---|
| Particulars | 202606 | 202506 | Var.(%) | 202603 | 202503 | Var.(%) |
|---|
| Net Sales (including other operating income) | 735.20 | 1,328.90 | -44.68 | 4,078.30 | 4,429.50 | -7.93 | | OPM (%) | 25.37 | 42.97 | -1,760 bps | 35.22 | 49.58 | -1,435 bps | | OP | 186.50 | 571.00 | -67.34 | 1,436.50 | 2,196.00 | -34.59 | | Other Inc. | 59.20 | 61.70 | -4.05 | 297.60 | 354.50 | -16.05 | | PBIDT | 245.70 | 632.70 | -61.17 | 1,734.10 | 2,550.50 | -32.01 | | Interest | 13.00 | 3.20 | 306.25 | 36.70 | 23.90 | 53.56 | | PBDT | 232.70 | 629.50 | -63.03 | 1,697.40 | 2,526.60 | -32.82 | | Depreciation | 47.1 | 57.6 | -18.23 | 206.6 | 235.2 | -12.16 | | PBT | 185.60 | 571.90 | -67.55 | 1490.8 | 2291.4 | -34.94 | | Share of Profit/(Loss) from Associates | 84.3 | 0 | - | 46.6 | 0 | - | | PBT before EO | 269.9 | 571.9 | -52.81 | 1537.4 | 2291.4 | -32.91 | | EO Income | 0 | 0 | - | 0 | 0 | - | | PBT after EO | 269.9 | 571.9 | -52.81 | 1537.4 | 2291.4 | -32.91 | | Taxation | 63.4 | 91.6 | -30.79 | 118.9 | 408 | -70.86 | | PAT | 206.5 | 480.3 | -57.01 | 1418.5 | 1883.4 | -24.68 | | Minority Interest (MI) | 0 | -0.4 | - | 0 | -2 | - | | Net profit | 206.5 | 480.7 | -57.04 | 1418.5 | 1885.4 | -24.76 | | P/(L) from discontinued operations net of tax | 0 | 0 | - | 0 | 0 | - | | Net profit after discontinued operations | 206.5 | 480.7 | -57.04 | 1418.5 | 1885.4 | -24.76 | | EPS (Rs)* | 11.53 | 26.84 | -57.04 | 79.20 | 105.27 | -24.76 | | | * EPS is on current equity of Rs 35.82 crore, Face value of Rs 2, Excluding extraordinary items. | | # EPS is not annualised | | bps : Basis points | | EO : Extraordinary items | | Figures in Rs crore | | Source: Capitaline Corporate Database |
|
| Natco Pharma : Consolidated Segment Results | | | Quarter ended | Year ended |
|---|
| % of (Total) | 202606 | 202506 | Var.(%) | % of (Total) | 202603 | 202503 | Var.(%) |
|---|
| Sales | | Pharmaceutical | 94.45 | 694.40 | 1,294.20 | -46.35 | 96.61 | 3,940.10 | 4,368.90 | -9.81 | | Agro Chemical | 5.55 | 40.80 | 34.70 | 17.58 | 3.39 | 138.20 | 60.60 | 128.05 | | Total Reported Sales | 100.00 | 735.20 | 1,328.90 | -44.68 | 100.00 | 4,078.30 | 4,429.50 | -7.93 | | Less: Inter segment revenues | | 0.00 | 0.00 | - | | 0.00 | 0.00 | - | | Net Sales | 100.00 | 735.20 | 1,328.90 | -44.68 | 100.00 | 4,078.30 | 4,429.50 | -7.93 | | PBIT | | Pharmaceutical | 102.67 | 203.90 | 578.30 | -64.74 | 101.30 | 1,547.30 | 2,461.10 | -37.13 | | Agro Chemical | -2.67 | -5.30 | -3.20 | -65.62 | -1.30 | -19.80 | -145.80 | 86.42 | | Total PBIT | 100.00 | 198.60 | 575.10 | -65.47 | 100.00 | 1,527.50 | 2,315.30 | -34.03 | | Less : Interest | | 13.00 | 3.20 | 306.25 | | 36.70 | 23.90 | 53.56 | | Add: Other un-allcoable | | 0.00 | 0.00 | - | | 0.00 | 0.00 | - | | PBIT Margin(%) | | Pharmaceutical | | 29.36 | 44.68 | -1,532.05 | | 39.27 | 56.33 | -1,706.17 | | Agro Chemical | | -12.99 | -9.22 | -376.83 | | -14.33 | -240.59 | 22,626.70 | | PBT | 100.00 | 185.60 | 571.90 | -67.55 | 100.00 | 1,490.80 | 2,291.40 | -34.94 |
|
|